Advances in Sustained Delivery of Anti-VEGF Therapy: Prepare for Practice Change
Release Date: September 30, 2020
Last Reviewed: September 22, 2020
Expiration Date: September 30, 2021
Time to Complete Activity: 1.5 Hours
Arshad M. Khanani, MD, MA
Clinical Associate Professor
University of Nevada, Reno School of Medicine
Managing Partner, Director of Clinical Research, Director of Fellowship
Sierra Eye Associates
Carl D. Regillo, MD, FACS
Director, the Retina Service of Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Partner, Mid Atlantic Retina
This activity is provided by Paradigm Medical Communications, LLC.
This activity has been designed to address the educational needs of retina specialists. It may also benefit comprehensive ophthalmologists and other clinicians involved in the care of patients with neovascular retinal diseases.
Upon proper completion of this activity, participants should be better able to:
- Develop anti-vascular endothelial growth factor (VEGF) treatment strategies that have been demonstrated to improve visual acuity and anatomical outcomes, and to halt disease progression
- Evaluate clinical trial designs, safety, and efficacy for novel strategies under investigation for sustained delivery of anti-VEGF agents used to treat neovascular retinal diseases
- Describe appropriate surgical techniques for the implantation and/or refill of novel anti-VEGF delivery strategies, as well as common pitfalls that should be avoided
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Instructions for Participation
To receive a CME certificate of participation, you should:
- Follow instructions to register or log in with your professional information and complete the preactivity assessment
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
Technical Support: If you have any technical problems or playback issues, email us at email@example.com.
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Arshad M. Khanani, MD, MA
Consultant: Adverum Biotechnologies, Inc; Allergan, Inc; Bausch and Lomb Incorporated; Chengdu Kanghbing Pharmaceutical Group Co, Ltd; Eyepoint Pharmaceuticals; Gemini Therapeutics; Genentech, Inc; Graybug; Gyroscope Therapeutics Limited; Kodiak Sciences, Inc; Novartis; Opthea; Oxurion NV; Recens Medical; Regenxbio, Inc
Grant/Research Support: Adverum Biotechnologies, Inc; Allergan, Inc; Chengdu Kanghbing Pharmaceutical Group Co, Ltd; Genentech, Inc; Graybug; Gemini Therapeutics; Gyroscope Therapeutics Limited; IVERIC bio; Kodiak Sciences, Inc; Novartis; Opthea; Oxurion NV; Recens Medical; Roche; Regenxbio, Inc
Speakers Bureau: Allergan, Inc; Novartis
Carl D. Regillo, MD
Consultant: Adverum Biotechnologies, Inc; Allergan, Inc; Genentech, Inc; Kodiak Sciences, Inc; Novartis
Grant/Research Support: Adverum Biotechnologies, Inc; Allergan, Inc; Genentech, Inc; Kodiak Sciences, Inc; Novartis; Regeneron Pharmaceuticals, Inc
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
One independent peer reviewer has no financial relationships to disclose.
Peer reviewer Sunir J. Garg, MD has the following relationships to disclose:
Consultant: Allergan, Inc; Bausch and Lomb Incorporated; Deciphera Pharmaceuticals, LLC; Johnson & Johnson Services, Inc; TopiVert
Grant/Research Support: Aerpio Pharmaceuticals; Apellis Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Regeneron Pharmaceuticals, Inc
Resident reviewer, Samir N. Patel, MD, has no financial relationships to disclose.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity has been independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for use have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
© 2020 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.